TIFFANY CHAILLE: Open Payments
NPI 1932655982 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,608 in 41 payments from 13 companies in 2025. Trend: 2023 $1,400 · 2024 $1,651 · 2025 $1,608
Food & beverage: $1,497Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $320 |
| Janssen Pharmaceuticals, Inc | 5 | $279 |
| Vanda Pharmaceuticals Inc. | 5 | $211 |
| Neurocrine BioSciences, Inc. | 2 | $138 |
| Alkermes, Inc. | 2 | $123 |
| E.R. Squibb & Sons, L.L.C. | 2 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Axsome Therapeutics, Inc. | 4 | $90 |
| ABBVIE INC. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $66 |
Products named: INVEGA SUSTENNA, FANAPT, UZEDY, INGREZZA, ARISTADA, COBENFY, Auvelity, REXULTI.
Industry payments across NY — which companies pay providers there.
